Heart Patients Need to Avoid Weight-Loss Drug Meridia

The U.S. Food and Drug Administration (FDA) is again alerting healthcare professionals that the prescription weight-loss drug sibutramine, marketed in the U.S. as Meridia, is contraindicated in patients with a history of cardiovascular disease, due to increase risk of heart attack and stroke.
Last January, at the behest of the FDA, Meridia’s manufacturer Abbott Laboratories agreed to add new contraindications on materials for the drug after reviewing additional data from the Sibutramine Cardiovascular Morbidity/Mortality Outcomes in Overweight or Obese Subjects at Risk of a Cardiovascular Event (SCOUT) study.

http://www.healthnews.com/nutrition-diet/weight-loss/heart-patients-need-to-avoid-weight-loss-drug-meridia-4177.html